Volume 3, Issue 11 p. 2200-2207
Research Article

Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity

Kerri Bouwman

Kerri Bouwman

The Van Andel Research Institute, Grand Rapids, MI, USA

Search for more papers by this author
Ji Qiu

Ji Qiu

University of Michigan Medical School, Ann Arbor, MI, USA

Search for more papers by this author
Heping Zhou

Heping Zhou

The Van Andel Research Institute, Grand Rapids, MI, USA

Search for more papers by this author
Mark Schotanus

Mark Schotanus

The Van Andel Research Institute, Grand Rapids, MI, USA

Search for more papers by this author
Leslie A. Mangold

Leslie A. Mangold

The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Search for more papers by this author
Robert Vogt

Robert Vogt

NovoDynamics, Ann Arbor, MI, USA

Search for more papers by this author
Erik Erlandson

Erik Erlandson

NovoDynamics, Ann Arbor, MI, USA

Search for more papers by this author
John Trenkle

John Trenkle

NovoDynamics, Ann Arbor, MI, USA

Search for more papers by this author
Alan W. Partin

Alan W. Partin

The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Search for more papers by this author
David Misek

David Misek

University of Michigan Medical School, Ann Arbor, MI, USA

Search for more papers by this author
Gilbert S. Omenn

Gilbert S. Omenn

University of Michigan Medical School, Ann Arbor, MI, USA

Search for more papers by this author
Brian B. Haab

Corresponding Author

Brian B. Haab

The Van Andel Research Institute, Grand Rapids, MI, USA

The Van Andel Research Institute, 333 Bostwick NE, Grand Rapids, MI 49503, USA Fax: +1-616-234-5269===Search for more papers by this author
Samir Hanash

Samir Hanash

University of Michigan Medical School, Ann Arbor, MI, USA

Search for more papers by this author
First published: 27 October 2003
Citations: 64

Abstract

The broad characterization of the immune responses elicited by tumors has valuable applications in diagnostics and basic research. We present here the use of microarrays of tumor-derived proteins to profile the antibody repertoire in the sera of prostate cancer patients and controls. Two-dimensional liquid chromatography was used to separate proteins from the prostate cancer cell line LNCaP into 1760 fractions. These fractions were spotted in microarrays on coated microscope slides, and the microarrays were incubated individually with serum samples from 25 men with prostate cancer and 25 male controls. The amount of immunoglobulin bound to each fraction by each serum sample was quantified. Statistical analysis revealed that 38 of the fractions had significantly higher levels of immunoglobulin binding in the prostate cancer samples compared to the controls. Two fractions showed higher binding in the control samples. The significantly higher immunoglobulin reactivity from the prostate cancer samples may reflect a strong immune response to the tumors in the prostate cancer patients. We used multivariate analysis to classify the samples as either prostate cancer or control. In a cross-validation study, recursive partitioning classified the samples with 84% accuracy. A decision tree with two levels of partitioning classified the samples with 98% accuracy. Additional studies will allow further characterization of tumor antigens in prostate cancer and their significance for diagnosis. These results suggest that microarrays of fractionated proteins could be a powerful tool for tumor antigen discovery and cancer diagnosis.